Systemic lupus erythematosus: Difference between revisions

(12 intermediate revisions by 5 users not shown)
Line 1: Line 1:
==Background==
==Background==
*Autoimmune disorder affecting all systems
*Autoimmune disorder affecting all systems
*Also consider drug induced lupus


===Epidemiology===
===Epidemiology===
*Female:Male 10:1
*Female:Male 10:1
*Peak in 20s-30s
*Peak in 20s-30s
*More common in African Americans
*More common in Black patients


==Clinical Features==
==Clinical Features==
[[File:Lupusfoto.jpg|thumb|Typical "butterfly" malar rash.]]
[[File:PMC3410306 AD2012-834291.004.png|thumb|Palatal ulcer in SLE]]
[[File:PMC3410306 AD2012-834291.005.png|thumb|Subacute cutaneous SLE]]
'''SLICC Classification Criteria 2012''' <ref>Lisnevskaia L, et al. Systemic Lupus Erythematosus. Lancet. 2014 May 29. Epub ahead of print.</ref>
'''SLICC Classification Criteria 2012''' <ref>Lisnevskaia L, et al. Systemic Lupus Erythematosus. Lancet. 2014 May 29. Epub ahead of print.</ref>
Requirements: >4 of the following criteria (at least 1 clinical and 1 laboratory) '''OR''' biopsy proven lupus nephritis with  
Requirements: >4 of the following criteria (at least 1 clinical and 1 laboratory) '''OR''' biopsy proven lupus nephritis with  
positive ANA or Anti-dsDNA
positive ANA or Anti-dsDNA
*Clinical criteria
*Clinical criteria
**Malar rash, bullous lupus, photosensitivity
**Malar [[rash]], bullous lupus, photosensitivity
**Discoid rash, hypertrophic lupus
**Discoid rash, hypertrophic lupus
**Oral ulcers or nasal ulcers
**Oral ulcers or nasal ulcers
Line 18: Line 22:
**Synovitis
**Synovitis
**Serositis
**Serositis
**Nephritis
**[[glomerulonephritis|Nephritis]]
**Cerebritis, myelitis, neuropathy
**Cerebritis, myelitis, neuropathy
**Hemolytic anemia
**[[Hemolytic anemia]]
**Leukopenia or lymphopenia
**[[Leukopenia]] or lymphopenia
**Thrombocytopenia
**[[Thrombocytopenia]]


*Immunological criteria
*Immunological criteria
Line 34: Line 38:
'''Organ system affected:'''
'''Organ system affected:'''
*Cardiopulmonary
*Cardiopulmonary
**Pneumonia
**[[Pneumonia]]
***Cover for ''[[Listeria]]'' and ''[[Pseudomonas]]''
***Cover for ''[[Listeria]]'' and ''[[Pseudomonas]]''
**CAD
**CAD
Line 43: Line 47:
***Infectious and Libman-Sachs
***Infectious and Libman-Sachs


*Neuropsychiatric/Altered mental status
*Neuropsychiatric/[[Altered mental status]]
**Non-convulsive status epilepticus
**Non-convulsive [[status epilepticus]]
**CNS vasculitis
**CNS [[vasculitis]]
**[[Stroke]]
**[[Stroke]]
**[[Encephalitis]]
**[[Encephalitis]]
Line 51: Line 55:


*Musculoskeletal
*Musculoskeletal
**Arthritis
**[[Arthritis]]
***Usually symmetric
***Usually symmetric
***Consider septic arthritis if there is a single inflamed joint
***Consider [[septic arthritis]] if there is a single inflamed joint
****Cover for [[Salmonella]] in addition to standard coverage
****Cover for [[Salmonella]] in addition to standard coverage


*GI
*GI
**Lupus enteritis (mesenteric vasculitis)
**Lupus enteritis (mesenteric [[vasculitis]])
***Most common cause of acute abdominal pain
***Most common cause of acute [[abdominal pain]]
**[[Pancreatitis]]
**[[Pancreatitis]]
**PUD
**[[PUD]]


*Dermatologic
*Dermatologic
**Malar rash across bridge of nose
**Malar [[rash]] across bridge of nose
**Discoid rash, erythematous with scale
**Discoid rash, erythematous with scale
**Treat with topical 1% hydrocortisone


*Renal
*Renal
**Usually a nephritis
**Usually a [[glomerulonephritis|nephritis]]
**Can cause a glomerulonephrosis
**Can cause a glomerulonephrosis


==Differential Diagnosis==
==Differential Diagnosis==
*[[Rheumatoid arthritis]]
*[[Rheumatoid arthritis]]
*[[Sjogren's syndrome]]
*[[Sjögren Syndrome]]
*[[Dermatomyositis]]
*[[Dermatomyositis]]
*[[Polymyositis]]
*[[Polymyositis]]
Line 80: Line 83:
*[[Septic Arthritis]]
*[[Septic Arthritis]]
*[[Lyme Disease]]
*[[Lyme Disease]]
*Vasculitis
*[[Vasculitis]]
*[[Acute Rheumatic Fever]]
*[[Acute Rheumatic Fever]]
*[[Toxic Shock Syndrome]]
*[[Toxic Shock Syndrome]]
Line 86: Line 89:
*[[Idiopathic Thrombocytopenic Purpura|ITP]]
*[[Idiopathic Thrombocytopenic Purpura|ITP]]
*[[DIC]]
*[[DIC]]
{{Differential Diagnosis Polyarthritis}}


{{Glomerulonephritis causes}}
{{Glomerulonephritis causes}}


==Diagnosis==
==Evaluation==
'''Undiagnosed'''
'''Undiagnosed'''
*CBC
*CBC
Line 96: Line 101:
*ANA
*ANA
*ESR
*ESR
*UA
*[[Urinalysis]]
*Bedside echo if ill or hypotensive
*Bedside [[echocardiography]] if ill or hypotensive
*(Consider anti-DNA, anti-Smith, anti-Nuclear, anti-phospholipid, C3,C4, direct Coombs')
*(Consider anti-DNA, anti-Smith, anti-Nuclear, anti-phospholipid, C3,C4, direct Coombs')


Line 104: Line 109:
*CBC
*CBC
*Chem
*Chem
*UA
*[[Urinalysis]]
*Urine pregnancy
*Urine pregnancy
*As directed by organ system involved
*As directed by organ system involved


===Fever in SLE===
'''Drug Induced Lupus'''
*Anti-histone-Ab positive 95% of the time
*Make sure to review medications
**High risk:
***[[Procainamide]] (antiarrhythmic)
***[[Hydralazine]] (antihypertensive)
**Moderate to low risk:
***Infliximab anti (TNF-α)
***Etanercept anti (TNF-α)
***[[Isoniazid]] (antibiotic)
***[[Minocycline]] (antibiotic)
***[[Pyrazinamide]] (antibiotic)
***[[Quinidine]] (antiarrhythmic)
***D-[[Penicillamine]] (anti-inflammatory)
***[[Carbamazepine]] (anticonvulsant)
***[[Oxcarbazepine]] (anticonvulsant)
***[[Phenytoin]] (anticonvulsant)
***Propafenone (antiarrhythmic)
***[[Chlorpromazine]] (antipsychotic)
 
===[[Fever]] in SLE===
*Must differentiate disease activity (flare) from infection
*Must differentiate disease activity (flare) from infection


'''Risk Factors for Infection''' <ref>Cuchacovich, R., & Gedalia, A. (2009). Pathophysiology and clinical spectrum of infections in systemic lupus erythematosus. Rheumatic diseases clinics of North America, 35(1), 75–93. doi:10.1016/j.rdc.2009.03.003</ref>
'''Risk Factors for Infection''' <ref>Cuchacovich, R., & Gedalia, A. (2009). Pathophysiology and clinical spectrum of infections in systemic lupus erythematosus. Rheumatic diseases clinics of North America, 35(1), 75–93. doi:10.1016/j.rdc.2009.03.003</ref>
*Neutropenia/Lymphopenia
*[[Neutropenia]]/Lymphopenia
*Hypocomplementemia
*Hypocomplementemia
*Immunosuppressive therapy (especially Azathioprine <ref>Zhou, W. J., & Yang, C.-D. (2009). The causes and clinical significance of fever in systemic lupus erythematosus: a retrospective study of 487 hospitalised patients. Lupus, 18(9), 807–812. doi:10.1177/0961203309103870</ref>)
*Immunosuppressive therapy (especially [[azathioprine]] <ref>Zhou, W. J., & Yang, C.-D. (2009). The causes and clinical significance of fever in systemic lupus erythematosus: a retrospective study of 487 hospitalised patients. Lupus, 18(9), 807–812. doi:10.1177/0961203309103870</ref>)


'''Studies'''
'''Studies'''
Line 122: Line 147:
==Management==
==Management==
*Inflammatory complications
*Inflammatory complications
**Methylprednisolone 1-2mg/kg in most cases
**[[Methylprednisolone]] 1-2mg/kg in most cases
*Infectious
*Infectious
**Stress dose steroids with hydrocortisone 100mg IV Q8hr if on or recently on steroids
**Stress dose steroids with [[hydrocortisone]] 100mg IV Q8hr if on or recently on steroids
 
*Dermatologic
*Dermatologic
**Hydrocortisone 1% cream
**[[Hydrocortisone]] 1% cream
*If drug induced lupus, stop medication and consider alternative


==Disposition==
==Disposition==
Line 133: Line 158:
*Mild flairs can have expedited out patient management
*Mild flairs can have expedited out patient management
*Musculoskeletal symptoms can usually be managed as out patients
*Musculoskeletal symptoms can usually be managed as out patients
*Chest pain requires urgent ACS evaluation
*[[Chest pain]] requires urgent ACS evaluation
*Infections usually require admission for antibiotics and systemic corticosteroids
*Infections usually require admission for antibiotics and systemic corticosteroids


Line 148: Line 173:
<references/>
<references/>


[[Category: Rheum]]
[[Category:Rheumatology]]

Revision as of 04:16, 27 November 2019

Background

  • Autoimmune disorder affecting all systems
  • Also consider drug induced lupus

Epidemiology

  • Female:Male 10:1
  • Peak in 20s-30s
  • More common in Black patients

Clinical Features

Typical "butterfly" malar rash.
Palatal ulcer in SLE
Subacute cutaneous SLE

SLICC Classification Criteria 2012 [1] Requirements: >4 of the following criteria (at least 1 clinical and 1 laboratory) OR biopsy proven lupus nephritis with positive ANA or Anti-dsDNA

  • Immunological criteria
    • ANA
    • Anti-dsDNA
    • Anti-Sm
    • Antiphospholipid antibody
    • Low complement C3, low C4
    • Direct Coombs' test in the absence of haemolytic anaemia

Organ system affected:

  • Dermatologic
    • Malar rash across bridge of nose
    • Discoid rash, erythematous with scale
  • Renal
    • Usually a nephritis
    • Can cause a glomerulonephrosis

Differential Diagnosis

Polyarthritis

Algorithm for Polyarticular arthralgia

Causes of Glomerulonephritis

Evaluation

Undiagnosed

  • CBC
  • Chem 10
  • Urine pregnancy
  • ANA
  • ESR
  • Urinalysis
  • Bedside echocardiography if ill or hypotensive
  • (Consider anti-DNA, anti-Smith, anti-Nuclear, anti-phospholipid, C3,C4, direct Coombs')

Flare

  • Bedside echo if ill or hypotensive
  • CBC
  • Chem
  • Urinalysis
  • Urine pregnancy
  • As directed by organ system involved

Drug Induced Lupus

Fever in SLE

  • Must differentiate disease activity (flare) from infection

Risk Factors for Infection [2]

Studies

  • CRP: sensitivity 100%, specificity 90% >1.35mg/dL [4]
  • PCT: sensitivity 75%, specificity 75% [5]

Management

  • Inflammatory complications
  • Infectious
    • Stress dose steroids with hydrocortisone 100mg IV Q8hr if on or recently on steroids
  • Dermatologic
  • If drug induced lupus, stop medication and consider alternative

Disposition

  • Suspected new diagnosis can have out patient workup if well appearing
  • Mild flairs can have expedited out patient management
  • Musculoskeletal symptoms can usually be managed as out patients
  • Chest pain requires urgent ACS evaluation
  • Infections usually require admission for antibiotics and systemic corticosteroids

See Also

References

  1. Lisnevskaia L, et al. Systemic Lupus Erythematosus. Lancet. 2014 May 29. Epub ahead of print.
  2. Cuchacovich, R., & Gedalia, A. (2009). Pathophysiology and clinical spectrum of infections in systemic lupus erythematosus. Rheumatic diseases clinics of North America, 35(1), 75–93. doi:10.1016/j.rdc.2009.03.003
  3. Zhou, W. J., & Yang, C.-D. (2009). The causes and clinical significance of fever in systemic lupus erythematosus: a retrospective study of 487 hospitalised patients. Lupus, 18(9), 807–812. doi:10.1177/0961203309103870
  4. Kim, H.-A., Jeon, J.-Y., An, J.-M., Koh, B.-R., & Suh, C.-H. (2012). C-reactive protein is a more sensitive and specific marker for diagnosing bacterial infections in systemic lupus erythematosus compared to S100A8/A9 and procalcitonin. The Journal of rheumatology, 39(4), 728–734. doi:10.3899/jrheum.111044
  5. Scirè, C. A., Cavagna, L., Perotti, C., Bruschi, E., Caporali, R., & Montecucco, C. (2006). Diagnostic value of procalcitonin measurement in febrile patients with systemic autoimmune diseases. Clinical and experimental rheumatology, 24(2), 123–128.